Hidradenitis suppurativa (HS) is a chronic, inflammatory condition predominantly affecting younger adults and disproportionately affecting women and Black Americans. Estimated prevalences vary significantly according to study methodology; however, true prevalence may range from approximately 0.1% to 1%. Hidradenitis suppurativa is associated with a number of comorbid conditions which also contribute to poor health outcomes and negative impact on quality of life. Recent advancements in our understanding of disease burden in hidradenitis suppurativa have allowed us to identify subgroups of the population afflicted with the disease and to implement strategies which facilitate comprehensive care.

Hidradenitis suppurativa is a debilitating inflammatory disease with a profound impact on quality of life for affected patients and caregivers. The patient journey in hidradenitis begins with symptom onset and proceeds through diagnosis and treatment. It is fraught with misdiagnosis, lack of awareness, misinformation, and inappropriate treatments that lead to shame, blame, isolation, and medical mistrust. This review highlights the relationship between hidradenitis and quality of life, emphasizing the patient journey and opportunities to improve care along its tortuous course.

To the Editor: Vancomycin accounts for a sizable portion of drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS)1 and is associated with 10% to 40% higher rate of organ involvement than overall DiHS/DRESS.2 Research is lacking describing the characteristics of vancomycin associated DiHS/DRESS specifically and the etiology behind extensive organ involvement in these cases. The purpose of this study was to describe vancomycin associated DiHS/DRESS and investigate clinical variables related to organ involvement.